REC-994
REC-994small moleculeoxidative stress modulator (CCM)
Recurrent Glioblastoma
Phase 2
1 program·1 trial·View drug →
DashboardOption ex.2,774$15.33$42.5KSell8,736$16.64−$145.4KSell19,139$14.06−$269.1K NeurologyCo-Investigator$771.2K6NeurologyCo-Investigator$747.0K3NeurologyCo-Investigator$603.5K7NeurologyCo-Investigator$444.0K7NeuromuscularEquity / Ownership$393.1K4NeurologyCo-Investigator$246.6K3NeurologyConsulting$28.2K2
RXRXNASDAQ
Recursion
Recursion Pharmaceuticals, Inc. · Salt Lake City, UT · founded 2013
Recursion Pharmaceuticals is a Salt Lake City biotech that uses high-content phenomics imaging combined with machine learning to discover drug candidates. The platform photographs how millions of human cells respond to chemical and genetic perturbations and trains models to identify compounds that "rescue" disease-state cells, feeding clinical-stage programs in oncology and rare disease.
- Lead asset
- REC-994 · Ph2 · Recurrent Glioblastoma
- small molecule · oxidative stress modulator (CCM)
- Pipeline
- 1 drug · 1 program
- 1 Oncology - Solid
- Modalities
- small molecule×1
FocusOncology - SolidRare Disease
$4.80-2.04%1Y
RXRX · daily close · illustrative · 1 catalyst marked
PDUFA-44%
1Y high$5.041Y low$4.57range$0.47(10%)past catalysts
Peers in this space
BPMC$6.1B
Blueprint Medicines
Rel.
0.49
Oncology - Solidsmall molecule
1 programmatch: sector + modality
BMY$105.0B
Bristol Myers Squibb
Rel.
0.65
Cardiology - HFpEFsmall molecule
1 programmatch: modality
INCY$14.6B
Incyte
Rel.
0.72
Oncology - Hemesmall molecule
1 programmatch: modality
MDGL$6.8B
Madrigal
Rel.
0.57
NASH / MASHsmall molecule
1 programmatch: modality
AXSM$4.2B
Axsome Therapeutics
Rel.
0.58
Neurologysmall molecule
1 programmatch: modality
FOLD$2.9B
Amicus Therapeutics
Rel.
0.59
Rare Diseasesmall molecule
1 programmatch: modality
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph21
- Ph30
- Filed0
- Approved0
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Jun 29, 2025PDUFAREC-994 — PDUFA — CRL IssuedNegative-43.8%-25.5%-45.1%
Dec 31, 2024ReadoutREC-994 — Phase 3 Topline — Mixed ResultMixed+35.5%-29.9%-30.8%
Jan 6, 2024PDUFAREC-994 — PDUFA — ApprovedMixed+44.3%-21.9%-47.5%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 3 transactions · 3 insiders
Net flow
−$414.5K
Buys
$0
0 txns
Sells
$414.5K
2 txns
Largest
−$269.1K
SVP sell
Net flow per quarter · last 8Q
8 txns · sum −$333K
24Q325Q125Q326Q126Q2
buys · $333Ksells · $666K
Insider · roleActionSharesPriceValueDate
K. Hassan
CSO
Apr 21, 2026
T. Mendoza
COO
Apr 10, 2026
B. Voss
SVP
Feb 28, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
3 trades · 3 members
Est. net flow
−$3.37M
midpoint · brackets only
Buys
1
Sells
2
Party mix
0 D3 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
R
Sell$250K–$500K~$375KselfRep. Q. Yates
House · AL
Apr 24, 2026
filed +2d
R
Sell$1.00M–$5.00M~$3.00MdependentSen. B. Tucker
Senate · TN
Aug 24, 2025
filed +24d
R
Buy$1K–$15K~$8KjointSen. D. Greenwood
Senate · TX
May 18, 2025
filed +2d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
5 ETFs hold the position
Held by ETFs
$32.4M
aggregate position
Of market cap
2.95%
aggregate ETF share
Top holder
ARKK0.26%
ARK Innovation ETF
TickerETF · familyThemeNAV% of NAVPosition
ARKKInnovation$5.50B0.26%$14.3M
ARK Innovation ETF
ARK
XBIBroad biotech$7.90B0.13%$10.3M
SPDR S&P Biotech ETF
SPDR
SBIOSmall-cap biotech$110.0M4.31%$4.7M
ALPS Medical Breakthroughs ETF
First Trust
BBCSmall-cap biotech$60.0M5.07%$3.0M
Virtus LifeSci Biotech Clinical Trials
WisdomTree
PBEBroad biotech$175.0M0.03%$53K
Invesco Dynamic Biotechnology
Invesco
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
7 physicians paid · 32 disclosed records
Total 2025+2024
$3.23M
YoY
-81%
Co-Investigator$1.72MResearch Grant$830.4KEquity / Ownership$571.3KConsulting$59.4KSpeaking$35.2KTravel & Lodging$15.0KFood & Beverage$569
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Robert Tanaka
Penn Medicine
Dr. Anita Iyer
Mayo Clinic
Dr. Daniel Greene
MD Anderson
Dr. Vivian Mendoza
NYU Langone
Dr. Sarah Greene
UCSF
Dr. Charles Iyer
Memorial Sloan Kettering
Dr. Nadia Singh
Yale Medical
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$131K disclosed · 2 firms engaged
YoY change
+6%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Akin Gump Strauss Hauer & Feld$92K
7 quarters active
Squire Patton Boggs$39K
4 quarters active
Top issues lobbied
- Accelerated approval pathway reforms$66K
- Inflation Reduction Act drug-price negotiation$46K
- FDA user fee reauthorization (PDUFA / BsUFA)$20K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
1 award · 1 agency
Total awarded
$95.2M
across all programs
Active
$95.2M
option periods incl.
Top agency
BARDA$95.2M
largest active: Medical Countermeasure Stockpiling
AgencyTitle · type · award IDStatusValueAwarded → ends
BARDAactive$95.2MAug 2025→ Aug 2027
Medical Countermeasure Stockpiling
Contract · BAR-77526537
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
5 granted · 3 pending
Total in portfolio
8
Granted in last 12mo
2
Expiring < 2yr
0
Nearest expiry
Apr 2031
Patent #Title · inventor · drugTypeStatus · filedExpiry
11,413,695Formulation
Subcutaneous injectable formulations of REC-994
S. Voss + 3 · REC-994
grantedfiled Apr 2026
exp. Apr 2046
20.0y left
10,213,650Composition of Matter
Antibody-drug conjugates with novel linkers for REC-994
R. Greene + 4 · REC-994
grantedfiled Apr 2026
exp. Apr 2046
20.0y left
US 2026/2339991 A1Formulation
Stable lyophilized formulations of REC-994
M. Patel + 3 · REC-994
pendingfiled Apr 2026
in prosecution
10,292,213Composition of Matter
Modified RNA constructs and methods of use thereof REC-994
S. Chen + 3 · REC-994
grantedfiled Apr 2019
exp. Apr 2039
13.0y left
US 2020/7395860 A1Composition of Matter
Small molecule modulators of REC-994
T. Nguyen + 2 · REC-994
pendingfiled Apr 2020
in prosecution
11,399,624Composition of Matter
Bispecific antibody compositions targeting REC-994
A. Iyer + 3 · REC-994
grantedfiled Apr 2016
exp. Apr 2036
10.0y left
12,490,207Composition of Matter
Genome editing constructs encoding REC-994
B. Andersson + 3 · REC-994
grantedfiled Apr 2011
exp. Apr 2031
5.0y left
US 2009/1974685 A1Composition of Matter
Lipid nanoparticle formulations comprising REC-994
D. Goldstein + 3 · REC-994
pendingfiled Apr 2009
in prosecution
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
7 items from 4 categories
clinical4earnings1corporate1regulatory1
1d ago
RXRX reports Q4 results, reaffirms 2026 guidance
Business Wire·earnings
4d ago
RXRX doses first patient in Phase 3 REC-994 study
FierceBiotech·clinical
10d ago
RXRX announces $172 million private placement
Business Wire·corporate
29d ago
RXRX presents REC-994 data at major medical conference
FierceBiotech·clinical
2mo ago
RXRX announces interim analysis from REC-994 pivotal study
PR Newswire·clinical
2mo ago
RXRX completes enrollment in REC-994 Phase 2 trial
PR Newswire·clinical
2mo ago
FDA grants Breakthrough Therapy Designation to RXRX's REC-994
FierceBiotech·regulatory
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$4.80
Open
$4.83
Day Δ
-0.03
-0.62%
Day range
$4.77 – $4.86
52W range
$4.57 – $5.04
Avg daily volume
1.60M
Valuation & ownership
Enterprise value
$794M
Shares out
229.17M
Float
203.96M
Insider %
10.60%
Institutional %
45.60%
Beta
1.10
vs SPY · 52w
Balance sheet & burn
Cash + invest
$536M
Total debt
$60M
Debt / equity
4.60
Cash burn / Q
$51M
R&D spend TTM
$179M
33% of cash
ATM available
$55M
dilution risk
Earnings
EPS latest
$-0.75
EPS Δ vs prior
+0.00
EPS estimate
$-0.75
next quarter
EPS prior
$-0.75
Next earnings
May 13, 2026
Rev guidance
$17M